Weider Benefits from Robust Testing Demand, Achieves Record H1 Profit of NT$132 Million, EPS NT$2.9

Weider (7713-TW) has benefited from increasing demand for diagnostics in primary healthcare facilities, driven by population aging and the need for chronic disease management. This has led to robust growth in demand for in vitro diagnostic (IVD) reagents, boosting Weider's shipments and driving its first-half revenue to NT$618 million, with post-tax net profit reaching NT$132 million and earnings per share (EPS) at NT$2.9. All three metrics—revenue, net profit, and EPS—set new records for the same period.

In the second quarter, Weider reported revenue of NT$339 million, representing a 21.51% increase quarter-on-quarter and a 24.18% year-on-year rise. Gross margin improved to 36.4%, up 1.89 percentage points from the previous quarter and 4.02 percentage points year-on-year. Operating margin reached 26.96%, up 2 percentage points sequentially and 4.25 percentage points annually. Post-tax net profit amounted to NT$77 million, up 45.28% quarter-on-quarter and 54% year-on-year, with EPS at NT$1.73.

For the first half of the year, cumulative revenue reached NT$618 million, up 19.31% year-on-year. Gross margin stood at 35.6%, a 3.55 percentage point increase from the same period last year. Operating margin improved to 26.05%, up 4.43 percentage points year-on-year. Post-tax net profit was NT$132 million, up 45.1% year-on-year, with EPS at NT$2.9.

Looking ahead to the second half, Weider plans to deepen its 'Medical Testing Ecosystem' strategy by facilitating data integration between medical laboratories and clinics, enhancing collaboration with healthcare providers. The company will also accelerate the implementation of Laboratory Information System (LIS) projects to increase the revenue contribution from integrated medical information solutions. Overall, Weider maintains a positive outlook for full-year revenue growth.